Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. - Wikidata - awgldk - TriplyDB

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

http://www.wikidata.org/entity/Q33330270

about

Immunological Evasion in Glioblastoma Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Adoptive cell therapies for glioblastoma HMGB1 mediates endogenous TLR2 activation and brain tumor regression Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression Immunocompetent murine models for the study of glioblastoma immunotherapy The role of regulatory T cells in cancer.The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Dendritic cell-based human immunodeficiency virus vaccine.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors Immune microenvironments in solid tumors: new targets for therapy.Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.Recent developments on immunotherapy for brain cancer.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells Delicate balance among three types of T cells in concurrent regulation of tumor immunity.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model Naïve rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses.DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.Potential adenovirus-mediated gene therapy of glioma cancer.Challenges in clinical design of immunotherapy trials for malignant glioma.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma

P2860

Q26746612-CA9C3A29-D306-43C0-AB7E-9CFF88ADFEEC Q27014829-4823D5D2-C7BA-4E9D-8213-66EBA5AF60D6 Q27024830-C744ED34-0EAA-4492-9BED-B6F32EC470A4 Q27030863-568BA90D-15F4-4EF3-9FE1-31AB66191FCC Q27307459-95F974B5-45A4-4BC0-BA24-8C988ADF8C60 Q28087485-6ED124CC-225A-4928-9B11-AF354B284C7E Q28730798-981606AA-3159-494C-93FB-9308DDEBED7A Q28731711-D7329631-0A39-4554-803B-3E11F7499759 Q33551268-C41E0FF9-9FA7-4015-B325-4FE84B325F99 Q33574853-B711D705-59E0-445C-8BD9-74AC3A7F7EC6 Q33631986-D8BDA1E6-A38E-421F-8131-1D06EA353C71 Q33741769-F04E21BD-9260-4F70-A811-470BC35BE141 Q33800533-8737C113-AED2-4E83-817C-E805108BDBBE Q33837085-147A4FAD-E41D-46B4-B13C-DFDCC0C390F6 Q33874652-F7881AA7-656D-4E65-BBCE-96FC17BF08B1 Q33877450-F5D770AD-2F16-4F87-B50B-EE8486D748D5 Q34069598-186D5A0F-A727-471A-8706-03A0D677F4F1 Q34664957-583E4997-8450-4B8B-A509-F261892621F1 Q35020804-DA704676-DD26-4DFA-8A57-DCF11CCADCE0 Q35033249-073E0CC4-9DA3-4527-9E79-43392358C607 Q35220386-51CB92A8-DFD8-44E4-92AC-366237B7BB20 Q35285859-2D152261-F6B4-4E55-8BD5-BECFE93D59F8 Q35527165-C79D587D-647F-41E8-ACEE-FC1A8D97FEBD Q35570260-B528FF5B-45F4-4D4F-8595-6D2B8FEE7E5D Q35642044-34E72096-7454-4AC3-A1CC-79100F0B9F80 Q35828614-77EF1B95-1BD9-4D81-A50E-6E1FE70CDE9C Q35992355-15E56FD1-4DED-49D7-9F7D-AA43726666DC Q36086507-F3A85AF0-C17C-49A7-B91C-EB8204402860 Q36200438-73ABBF5B-2411-4A99-8A07-B85AD6E89DC9 Q36408364-E690F143-F2B9-4CCA-A34A-1C221B2554CF Q36755513-8EB748DB-60F4-411F-9371-F562A844742D Q36811505-9E7EFBBB-A922-41B8-B85C-38A03C6C807A Q36821149-32746546-9B52-4B96-89A9-CDB413D7AD3C Q36839728-F5550BEB-EE6D-4576-9301-CE4DF65390A4 Q37395354-55531842-CCF8-4B21-B5D6-617705723363 Q37403279-2160C3E1-15DF-41A8-927C-0C91542E52C3 Q37442739-59651301-0CD5-4C47-8AD5-F37C50BBCC68 Q37604185-0B05397D-8417-42C0-A5B9-C52F9BF9F462 Q37640613-86BDA12C-15C5-4275-AA53-519F1C31572E Q37730116-F9D9ACB6-9171-4429-8542-A583E7DFA475

P2860

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

http://www.wikidata.org/entity/Q33330270

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Treg depletion inhibits effica ...... lications for clinical trials.

@ast

Treg depletion inhibits effica ...... lications for clinical trials.

@en

Treg depletion inhibits effica ...... lications for clinical trials.

@nl

type

label

Treg depletion inhibits effica ...... lications for clinical trials.

@ast

Treg depletion inhibits effica ...... lications for clinical trials.

@en

Treg depletion inhibits effica ...... lications for clinical trials.

@nl

prefLabel

Treg depletion inhibits effica ...... lications for clinical trials.

@ast

Treg depletion inhibits effica ...... lications for clinical trials.

@en

Treg depletion inhibits effica ...... lications for clinical trials.

@nl

P1433

Q33330270-D7862483-1E07-4375-A839-C3821BAB725F

P1476

Q33330270-5AE521EC-83B9-49DA-96BD-0BF3A2325983

P2093

Q33330270-14EF4600-407F-4A7B-8344-5A8014B685F4

Q33330270-5B6812B0-119F-4036-9F2F-8B9A9EC9A944

Q33330270-84F4E46D-10C7-46F7-8681-48B39EE22220

Q33330270-A7795478-AB33-466C-9475-E677D7776A60

Q33330270-CCA5EBEC-FA05-418E-AFD5-7FBC82867CA6

Q33330270-E4503638-9CDE-4537-8BA4-23B23724F7A9

P2860

Q33330270-06228E71-BE44-44F0-9D00-56BBC1BC467C

Q33330270-0CFB8E83-7141-427B-8004-CAB5BE11A96A

Q33330270-0F8DA0C9-D1BA-4933-8C9E-E0005DCF756B

Q33330270-13AAD8C7-48E0-4CFE-B27A-C75A1174A67C

Q33330270-153A661D-5E79-4520-B064-FA3F43CE01AB

Q33330270-2064B927-2B76-494B-96CE-36B083A5479B

Q33330270-21EBF592-5A5B-4C96-9298-24384F50DDAD

Q33330270-28FAD3B9-6CA5-4B65-9AC7-B86EE8944BA1

Q33330270-2B2547C2-ADFE-4F13-9F38-F4D3DFB3EC2F

Q33330270-334C667F-107E-425D-BDE0-94CD0EF397D7

P304

Q33330270-2227D2E9-41A3-4FB7-8049-62D44A601995

P31

Q33330270-CDE5FBF1-9CCE-4BE9-810E-7D7F2B547A82

P356

Q33330270-3E5441CA-3D8C-4BD2-B222-119AC5700293

P407

Q33330270-AFDC1EF7-6EB5-4101-B32D-FD90C770615F

P433

Q33330270-6802E8EC-68AA-45A4-A505-DCF12B0F9D3B

P478

Q33330270-C3B987E4-35E6-4A4A-898D-0500CB4FFC5F

P50

Q33330270-33E46A4B-DD1C-4330-8B17-F6B82598464E

Q33330270-8B4D4536-0477-40D7-B4CF-E51368D54C7F

P577

Q33330270-B6CB13ED-D092-4312-AED5-E147AC4EBD84

P5875

Q33330270-42ECEC6F-E71B-4BA8-A977-6CBB625FC8AF

P698

Q33330270-1C28FF0A-6F84-43CF-B879-32BD24772267

P921

Q33330270-544D5E56-7335-4101-9BAC-FFCF03645CD6

P932

Q33330270-65D98B3F-3AC3-46C5-A0BE-922C9C341550

P356

JOURNAL.PONE.0001983

P1433

P1476

Treg depletion inhibits effica ...... lications for clinical trials.

@en

P2093

Anderson Alden

http://www.w3.org/2001/XMLSchema#string

Chunyan Liu

http://www.w3.org/2001/XMLSchema#string

Marianela Candolfi

http://www.w3.org/2001/XMLSchema#string

Matthew Edwards

http://www.w3.org/2001/XMLSchema#string

Pedro R Lowenstein

http://www.w3.org/2001/XMLSchema#string

Tamer M Fakhouri

http://www.w3.org/2001/XMLSchema#string

P2860

Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes

The three Es of cancer immunoediting

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

The immunobiology of cancer immunosurveillance and immunoediting

X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

Primary brain tumours in adults.

Epidemiology and etiology of gliomas.

Combining cytotoxic and immune-mediated gene therapy to treat brain tumors

P304

e1983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0001983

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5245235

http://www.w3.org/2001/XMLSchema#string

P698

18431473

http://www.w3.org/2001/XMLSchema#string

P921

P932

2291560

http://www.w3.org/2001/XMLSchema#string